The AGILE Team
AGILE is a collaboration between the University of Liverpool, Southampton Clinical Trials Unit, and other external partners. The team includes Infectious Diseases clinicians, clinical and pre-clinical pharmacologists, clinical trials specialists and statisticians, each bringing a unique set of skills and expertise to design the best platform possible.
Saye Khoo is Professor of Pharmacology and Therapeutics at the University of Liverpool and Honorary Consultant Physician in Infectious Disease at Liverpool University Hospitals NHS Foundation Trust. He leads a research programme in antiviral therapy and is Chief Investigator for the international DolPHIN consortium and for AGILE.
Gareth Griffiths is the Director of the UKCRC registered Southampton Clinical Trials Unit (SCTU) and Professor of Clinical Trials based at the University of Southampton.
Helen Reynolds is a Programme Manager in Pharmacology and Therapeutics at the University of Liverpool and Honorary Clinical Research Nurse at Liverpool University Hospitals NHS Foundation Trust. She is a programme manager for the clinical trials in Prof. Saye Khoo’s antiviral research group that include the international DolPHIN consortium and AGILE.
Richard FitzGerald is Director of the NIHR Clinical Research Facility and a Consultant Physician in Clinical Pharmacology and Therapeutics / General Medicine at the Liverpool University Hospitals NHS Foundation Trust.
Emma Knox is a Senior Clinical Trials Manager at Southampton Clinical Trials Unit and the Biomedical Research Centre where she leads on the management of early phase COVID-19 clinical trials.
Tom Fletcher is Senior Clinical Lecturer at the Liverpool School of Tropical Medicine and a Defence Consultant in Infectious Diseases. He specialises in high consequence infectious diseases and is a long-term Consultant to the HQ WHO Clinical Team.
Lauren Walker is Deputy-Director of the NIHR Clinical Research Facility, Senior Clinical Lecturer at University of Liverpool and Honorary Consultant Physician in Clinical Pharmacology and General Medicine at Liverpool University Hospitals NHS Foundation Trust.
Michelle Tetlow is a Project Manager in Pharmacology and Therapeutics at the University of Liverpool. She has worked in clinical trials for over 20 years and has particular expertise within project and quality management, with an emphasis on setting up organisational quality systems.
Andrew Owen is Professor of Pharmacology and Director of the Centre of Excellence in Long-acting Therapeutics (CELT) at the University of Liverpool. He is Chair of the British Society for Nanomedicine, a fellow of the Royal Society of Biology, a fellow of the British Pharmacological Society, and a fellow of the Learned Society of Wales.
David Lalloo is Director and Professor of Tropical Medicine at the Liverpool School of Tropical Medicine. He has worked with the MLW Programme in Malawi for almost twenty years and holds an appointment as an Honorary Consultant at the Liverpool University Hospitals NHS Foundation Trust and remains clinically active.
Thomas Jaki is Professor of Statistics at Lancaster University and Programme Leader at the MRC Biostatistics Unit at the University of Cambridge. His work focuses on efficient trials using adaptive and Bayesian methods.
Geoff Saunders is a Senior Trial Statistician at Southampton Clinical Trials Unit and lead statistician for AGILE, which uses innovative Bayesian model-based dose-finding designs in a phase I setting. He also works across other trials within the SCTU including a range of cancer types and phases of trial.
Justin Chiong is a Programme Manager in the Department of Pharmacology and Therapeutics, University of Liverpool. He leads the finance & administration of the Infection Pharmacology Group’s research programme led by Prof Saye Khoo, as well as being involveed in the research activities of Liverpool Drug Interactions Programme, Bioanalytical Facility and other clinical trials.
Transparency and Conflicts of Interest
- Professor Saye Khoo has received research funding from ViiV, Merck, and Gilead unrelated to AGILE, support for the Liverpool Drug Interactions Resources from Viiv, Gilead, Merck, Janssen, Abbvie and speaker/consultancy fees from ViiV and Merck.
- Professor Andrew Owen is a Director and CSO for Tandem Nano Ltd and co-inventor of patents relating to drug delivery. AO has received research funding from ViiV Healthcare, Merck, and Janssen, as well as consultancy from Gilead, ViiV Healthcare and Merck not related to COVID19.
- Professor Gareth Griffiths has received funding from Janssen-Cilag, Astra Zeneca, Novartis, Astex, Roche, Heartflow, Celldex, BMS, BionTech, Cancer Research UK, NIHR, British Lung Foundation, GSK for unrelated academic clinical trials and programme funding.
- The Southampton Clinical Trials Unit has signed up to principles of AllTrials – https://www.alltrials.net/